Mercator Medical Group, a manufacturer of disposable gloves and distributor of medical supplies, reported PLN 436.2 million in consolidated sales revenue for the first three quarters of 2025—an 11% year-on-year increase (up PLN 42.9 million). Total glove sales reached 4.5 billion units, representing 10% growth compared with the same period in 2024.
Strong performance in the third quarter—PLN 145.2 million in revenue, with improved margins in both the distribution and production segments and higher sales volumes—enabled the Group to generate a cumulative positive EBITDA of PLN 8.2 million, compared with a loss in the same period last year. Net profit for the nine months of 2025 amounted to PLN 25.8 million, versus a PLN 22.3 million net loss a year earlier.
“Mercator Medical operates in a rapidly changing market environment where price pressure from Chinese manufacturers remains one of the key challenges. These conditions affect trading dynamics and require high operational flexibility from us. We continue to expand our product diversification. We closed another quarter with growing revenue from nonwoven products, which represent an increasingly significant share of our sales structure. Our aim is to strengthen our offer in this area, which in the long term should increase our resilience to market volatility,”
said Monika Żyznowska, CEO of Mercator Medical S.A.
United States Remains the Group’s Largest Market
As in previous quarters, the United States remained Mercator Medical’s largest market this year, accounting for 37% of total sales. After three quarters, sales in the U.S. reached PLN 161.3 million, up 44% year-on-year. This growth stemmed from the U.S. government’s active customs policy, which boosted local demand and weakened the competitive position of Chinese suppliers.
The Group also strengthened its presence in Central and Eastern Europe.
- In Romania, sales increased by nearly 20% y/y to PLN 28.3 million.
- In Poland, where the Group holds a leading market position, sales rose 4% y/y to PLN 106.1 million.
Improving Financial Stability and Profitability
“Q3 brought further operational stabilisation and improvement in key financial metrics. Consolidated sales revenue was up 4% y/y, and higher margins translated into EBITDA of PLN 8.9 million. Net profit reached PLN 4.5 million, compared to a PLN 27.2 million loss a year earlier. It is worth noting that the net result was significantly influenced by positive unrealised foreign exchange differences from the balance sheet valuation of loans granted by subsidiaries,”
said Mariusz Popek, Management Board Member of Mercator Medical S.A.
Real Estate Segment Gains Strategic Importance
Mercator Medical is also consistently expanding its real estate segment through its subsidiary Mercator Estates, which is becoming an important element of the Group’s diversification strategy. Preparations are underway for the revitalisation of a historic townhouse complex on Lubicz and Westerplatte streets in central Kraków, while additional projects are being planned.
